This company listing is no longer active
Dechra Pharmaceuticals (DPHL) Stock Overview
Dechra Pharmaceuticals PLC develops, manufactures, regulates, markets, and sells veterinary pharmaceuticals and related products for veterinarians. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
DPHL Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
Dechra Pharmaceuticals PLC Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£38.70 |
| 52 Week High | UK£38.84 |
| 52 Week Low | UK£24.74 |
| Beta | 0.78 |
| 1 Month Change | 0.55% |
| 3 Month Change | 2.27% |
| 1 Year Change | 35.79% |
| 3 Year Change | 5.91% |
| 5 Year Change | 63.71% |
| Change since IPO | 744.98% |
Recent News & Updates
Recent updates
Shareholder Returns
| DPHL | GB Pharmaceuticals | GB Market | |
|---|---|---|---|
| 7D | 0.2% | 2.1% | -1.8% |
| 1Y | 35.8% | 9.9% | 16.0% |
Return vs Industry: DPHL exceeded the UK Pharmaceuticals industry which returned -2.4% over the past year.
Return vs Market: DPHL exceeded the UK Market which returned -6.7% over the past year.
Price Volatility
| DPHL volatility | |
|---|---|
| DPHL Average Weekly Movement | 0.5% |
| Pharmaceuticals Industry Average Movement | 6.2% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in GB Market | 10.3% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: DPHL has not had significant price volatility in the past 3 months.
Volatility Over Time: DPHL's weekly volatility has decreased from 6% to 1% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 2,457 | Ian Page | www.dechra.com |
Dechra Pharmaceuticals PLC develops, manufactures, regulates, markets, and sells veterinary pharmaceuticals and related products for veterinarians. It operates through three segments: European Pharmaceuticals, North American Pharmaceuticals, and Pharmaceuticals. The company offers various endocrinology, dermatology, analgesia and anesthesia, cardiovascular, internal medicine, and nutrition products supporting cats and dogs with various therapeutic conditions, such as allergies, obesity, heart, and kidney diseases.
Dechra Pharmaceuticals PLC Fundamentals Summary
| DPHL fundamental statistics | |
|---|---|
| Market cap | UK£4.40b |
| Earnings (TTM) | -UK£27.90m |
| Revenue (TTM) | UK£761.50m |
Is DPHL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DPHL income statement (TTM) | |
|---|---|
| Revenue | UK£761.50m |
| Cost of Revenue | UK£331.90m |
| Gross Profit | UK£429.60m |
| Other Expenses | UK£457.50m |
| Earnings | -UK£27.90m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.24 |
| Gross Margin | 56.42% |
| Net Profit Margin | -3.66% |
| Debt/Equity Ratio | 64.6% |
How did DPHL perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/01/17 12:32 |
| End of Day Share Price | 2024/01/15 00:00 |
| Earnings | 2023/06/30 |
| Annual Earnings | 2023/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Dechra Pharmaceuticals PLC is covered by 14 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Samuel England | Berenberg |
| Laurent Gelebart | BNP Paribas |
| Keith Redpath | Cavendish |